Smoking Cessation Products Market Insights on Trends, Drivers and Opportunities until the End of 2028 || Key Players - Johnson & Johnson Inc., GlaxoSmithKline plc, Pfizer Inc., Perrigo Company plc, Cipla Ltd., ITC Limited, Reynolds American Inc.

The Fact.MR market report on the smoking cessation products market features a detailed analysis of the market, including information on the most interesting developments in the smoking cessation products market across the globe. The report provides an overview of the smoking cessation products market, analysis of the latest trends in the smoking cessation products market, along with a section with information about new avenues of growth for manufacturers and distributors in the smoking cessation products market.

A prevalence of around 251 million patients with COPD was report across the globe in 2016 by a WHO report, and it will become the third leading cause of death by 2030. As smoking tobacco is the primary cause of COPD, manufacturers in the smoking cessation products market are promoting the use of various types of smoking cessation products to prevent it.

Additionally, consumers are becoming aware that there is no cure for the life-threatening disease, thereby, the growing needs for preventing COPD is boosting adoption of smoking cessation products. Offering personalized smoking cessation products to facilitate COPD management for patients can help smoking cessation products market players to improve sales and gain an edge in the smoking cessation products market in coming years.

Request Free Sample Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2372

Governmental organizations across the world have introduced laws and regulations on marketing and distribution of smoking cessation products to address the public health concerns associated with tobacco use and use of smoking cessation products such as electronic cigarettes.

The U.S. Food and Drug Administration (FDA) has amended the Family Smoking Prevention and Tobacco Control Act and declared that vaping products and smoking cessation products, such as e-cigarettes, are subject to the Federal Food, Drug, and Cosmetic Act. The Government of Canada also enacted the Tobacco and Vaping Products Act (TVPA), which regulated manufacturing and sales of various smoking cessation products, including e-cigarettes, in Canada. Also, the UK Government introduced new rules under the Tobacco Products Directive 2014/14/EU (TPD) to regulate smoking cessation products, such as nicotine-containing electronic cigarettes and refill containers.

Leading countries enacting regulations on manufacturing, marketing, and distribution of e-cigarettes and other types of smoking cessation products is likely to create barriers for players in the smoking cessation products market.

Smoke-free air laws imposed by various national and international governmental organizations across various countries hold a major share in the growth of the smoking cessation products market. Smoke-free laws mainly aim at protecting consumers from secondhand smoking and restrict minors’ exposure to tobacco-smoking products.

The New Zealand government has developed ‘Smoke-free Environments Regulations 2007’, which imposed labeling requirements on all tobacco products to discourage smoking. Washington, DC, the U.S. capital, has imposed ‘The Department of Health Functions Clarification Amendment Act of 2006’ that bans smoking in most public places.

Growth prospects of the smoking cessation products market are moderately attributed to smoke-free air laws, as these laws limit promotion and advertising of tobacco products and indirectly encourage consumers to quit smoking. Stringent regulations and laws that discourage smoking may exhort the smoker population to turn to smoking cessation products, which may complement growth of the smoking cessation products market in the upcoming years.

Though most smoking cessation products can reduce withdrawal symptoms and help consumers to quit smoking tobacco with ease, they come with certain side effects leading to causing discomfort in consumers. The use of smoking cessation products, such as patches and nasal sprays, can cause irritation of nose, skin, eyes, or throat, along with causing some behavioral changes in consumers.

Also, insomnia and diarrhea are among the most common side effects of non-nicotine smoking cessation products, such as varenicline. FDA released a safety announcement to warn consumers about serious mental health side effects of smoking cessation products, including varenicline and bupropion. Growing consumer awareness about the potential risks of using smoking cessation products may hamper growth of the smoking cessation products market.

Outlook Complete Research Report with TOC @ https://www.factmr.com/report/2372/smoking-cessation-products-market

According to a report published by the World Health Organization (WHO), the number of deaths due to tobacco smoking, each year, has surpassed 7 million, making it one of the leading causes of deaths in the world. The report further reveals that there are over 1.1 billion tobacco smokers in the world and, assuming the constant prevalence, the number will reach around 1.8 billion, causing 10 million deaths due to tobacco smoking, by 2030.

Growing awareness about the health hazards of tobacco smoking is exhorting consumers, especially pregnant and lactating women, to start using smoking cessation products to quit smoking. As smoking cessation products can help tobacco smokers to keep away from the urge to smoke and reduce the incidences of tobacco-related illnesses, a majority of smokers are banking on smoking cessation products to quit smoking. This is likely to boost growth of the smoking cessation products market in the foreseeable future.

The Fact.MR report on smoking cessation products market enlists leading stakeholders in the market to provide insightful information about recent developments in the winning strategies of leading competitors in the smoking cessation products market. This chapter features comprehensive information, including intensity mapping, key financials, market share analysis, key developments, SWOT analysis, SIC, NACE, & NIACS codes, and global manufacturing facilities, about the each smoking cessation products market player mentioned above. The report provides detailed information about the leading market players including Johnson & Johnson Inc., GlaxoSmithKline plc, Pfizer, Inc, Perrigo Company plc, Cipla Ltd., ITC Limited, Reynolds American Inc., Imperial tobacco ltd., Fertin Pharma, and Alkalon A/S.

Johnson & Johnson Development Corp., a frontrunner in the smoking cessation products market, recently joined Carrot Inc., a digital health company New York Life Ventures and to raise over US$ 25 million to commercialize Pivot™ – smoking cessation program. The company is contributing to the project with its technological expertise in the medical device and pharmaceutical sector to establish stronger position in the smoking cessation products market.

Another frontrunner in the smoking cessation products market, GlaxoSmithKline plc. announced, in collaboration with an American pharmaceutical company – Innoviva, Inc., that the European Commission has authorized expansion of its single inhaler triple therapy – once-daily Trelegy Ellipta. The company is aiming to adopt innovative strategies to offer an inhaler therapy for COPD patients and strengthen its foothold in the smoking cessation products market.

Imperial Brands PLC, a British player in smoking cessation products market, has adopted strategies to focus on its blu e-cigarette brand by investing over GBP100 million for further expanding its e-cigarette product portfolio in the coming year. Via its subsidiary Fontem Ventures, the company launched its new e-smoking cessation product– myblu™ in the U.S. in February 2018, and later in three further markets – France, Russia, and Germany. With launch of the new e-smoking cessation product, Imperial Brands is aiming to set a benchmark in the e-vaporing category of products in the smoking cessation market.

Other players in the smoking cessation products market, including Cipla Ltd., are adopting innovative marketing strategies, such as promotions of social media and unique commercials to spread awareness about tobacco hazards, to boost sales of their smoking cessation products.

Have Any Query? Ask Our Industry Experts @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=2372

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

This release was published on openPR.